



# **FY17 2nd Quarter Financial Results [IFRS]**

October 25, 2017

Masahiro Miyazaki    President and Chief Executive Officer  
Shunichi Uno         Senior Vice President and Executive Officer

Hitachi High-Technologies Corporation

## **FY17 2nd Quarter Financial Results [IFRS]**

1. FY17 Q1-Q2 (Highlights)
2. Status of Progress on the Mid-Term Management Strategy
3. FY17 Outlook
4. Reference



## 1. FY17 Q1-Q2 (Highlights)

Note: YY/M denotes the year and month of the accounting period-end  
(e) denotes the figures announced on July 2017

# FY17 Q1-Q2 (Highlights)

(100 million yen)	FY17 1H Results	YoY		vs. Previous Forecast(e)	
		Increase / Decrease	Ratio	Increase / Decrease	Ratio
Revenues	3,356	+307	+10%	+56	+2%
Adjusted Operating Income*1	276	−10	−3%	+56	+25%
EBIT*2	271	−2	−1%	+51	+23%
Income before Income Taxes	272	−2	−1%	+52	+24%
Net Income	202	−7	−3%	+42	+26%
Net Income per Share	146.88 yen	−4.97 yen		+30.54 yen	
Cash Dividend per Share	40.00 yen	+5.00 yen		+5.00 yen	

Notes: ▪Exchange rate: 1USD=111 yen, 1EUR=126 yen

\*1 Adjusted operating income is presented as revenues less cost of sales as well as selling, general and administrative expenses

\*2 EBIT(Earnings before interest and taxes) is presented as income before income taxes less interest income and interest expenses

# FY17 Q1-Q2 (Revenues and EBIT by Segment)

(100 million yen)

		FY17 1H Results		FY16 1H Results		YoY		FY17 1H Outlook(e)	
		Revenues	EBIT	Revenues	EBIT	Revenues	EBIT	Revenues	EBIT
	Science & Medical Systems	876	97	926	145	-5%	-49	846	81
	Electronic Device Systems	701	178	572	136	+23%	+43	704	159
	Industrial Systems	338	-9	349	-0	-3%	-9	349	-6
	Advanced Industrial Products	1,475	19	1,249	8	+18%	+11	1,475	15
Total		3,356	271	3,048	273	+10%	-2	3,300	220

Note: • Elimination such as subtractions in intersegment transactions, etc., are included in the totals

• Under a business segment reorganization, some products in Industrial Systems were transferred to Advanced Industrial Products in FY17.  
FY16 Figures are restated

vs. Previous Forecast (July 2017)

Revenues (330.0 Ybn → 335.6 Ybn +5.6 Ybn)

■ Science & Medical Systems:	Increased 3.0 Ybn due to front-loaded sales of clinical analyzers and the establishment of Hitachi High-Tech Analytical Science Ltd.
------------------------------	--

EBIT (22.0 Ybn → 27.1 Ybn +5.1 Ybn)

■ Science & Medical Systems:	Increased 1.6 Ybn due mainly to front-loaded sales of clinical analyzers
■ Electronic Device Systems:	Increased 1.9 Ybn due mainly to growth in service businesses

# FY17 Q1-Q2 (Statement of Financial Position in Summary)

As of end of September 2017

(100 million yen)

			vs. 17/3				vs. 17/3
<b>Current Assets</b>		<b>4,620</b>	<b>-112</b>	<b>Current Liabilities</b>		<b>1,877</b>	<b>-110</b>
Cash and Cash Equivalents	<b>1,864</b>	<b>-34</b>		Trade Payables	<b>1,202</b>	<b>-11</b>	
Trade Receivables	<b>1,449</b>	<b>-17</b>		Others	<b>674</b>	<b>-99</b>	
Inventories	<b>1,065</b>	<b>+57</b>		<b>Non-Current Liabilities</b>		<b>316</b>	<b>-2</b>
Others	<b>241</b>	<b>-118</b>		Retirement and Severance Benefits	<b>269</b>	<b>+8</b>	
<b>Non-Current Assets</b>		<b>1,313</b>	<b>+167</b>	Others	<b>47</b>	<b>-10</b>	
Property, Plant and Equipment	<b>726</b>	<b>+18</b>		<b>Equity</b>		<b>3,740</b>	<b>+168</b>
Intangible Assets	<b>178</b>	<b>+99</b>		Total Hitachi High-Tech Stockholders' Equity	<b>3,736</b>	<b>+167</b>	
Others	<b>410</b>	<b>+51</b>		Non-controlling Interests	<b>4</b>	<b>+1</b>	
<b>Total Assets</b>		<b>5,933</b>	<b>+55</b>	<b>Total Liabilities &amp; Shareholder Equity</b>		<b>5,933</b>	<b>+55</b>

Note: ▪ Total Hitachi High-Tech Stockholders' Equity per Share: 2,716.79 yen (vs.17/3 +121.60 yen)

▪ Total Hitachi High-Tech Stockholders' Equity Ratio : 63.0%

**HITACHI**  
Inspire the Next

(100 million yen)		17/1H			17/1H
Cash Flow from Operating Activities		+113	Cash Flow from Financing Activities		-72
Net Income		+203	Dividends Paid		-62
Depreciation and Amortization		+57	Others		-10
Working Fund		-37	Effect of Exchange Rate Changes		+13
Income Tax Expense and Refund		-148			
Others		+38			
Cash Flow from Investing Activities		-88			
Proceeds from Sale / Purchase of Investments in Securities and Other Financial Assets		-144			
Proceeds from Sale / Purchase of Property, Plant, Equipment and Intangible Assets		-83			
Others		+139			
Free Cash Flow		+26			
			Cash and Cash Equivalents		17/1H
			At the Beginning of Year		1,898
			Net Increase (Decrease)		-34
			At the End of Term		1,864





## 2. Status of Progress on the Mid-Term Management Strategy

Note: YY/M denotes the year and month of the accounting period-end  
(e1) denotes the figures announced on April 2017  
(e2) denotes the figures announced on October 2017

# Mid-Term Management Strategy

(Material Disclosed with Financial Results in April 2016)

## KPI Formulate and execute growth strategies to achieve targets

**Revenues** Achieve progress beyond market growth  $\gg$  Revenues CAGR by business > Market growth rate

**Profitability** **Instruments** Maintain an EBIT margin of 10% or more

**Materials** Achieve an absolute EBIT of ¥5 billion or more (FY2018)

**Service ratio** Maintain the ratio of EBIT from service business\* to overall at 50% or more

## Investment strategy Proactively make investments to execute growth strategies

Size of Investment

(FY2016-FY2018 cumulative)

**R&D** **¥80 billion** Increase investments centered on the biotechnology and medical products business (Increase by 30% versus FY2013-FY2015)

**Capital investment** **¥40 billion**   
 • Manufacturing ability expansion, and technology strengthening to support business   
 • Strengthening collaboration with customers through demonstration facilities expansion

**Business investment** **¥30 billion**   
 Biotechnology and Healthcare Social and Industrial Infrastructure **+** Make additional business investments using cash on hand

## Shareholder returns Maintain a stable dividend, targeting a dividend payout ratio of 30%

\* Service business: product maintenance services, IT solutions, trading services, and others

# Status of Progress on the Mid-Term Management Strategy (1)

## Profitability

### Instruments

Maintain an EBIT margin of 10% or more

FY17 Outlook<sub>(e2)</sub>

FY17 Outlook<sub>(e1)</sub>

FY16 Results

- Maintained at 10% or more due to solid sales of metrology and inspection equipment

12%

11%

13%

### Materials

Achieve an absolute EBIT of ¥5 billion or more (FY2018)

FY17 Outlook<sub>(e2)</sub>

FY17 Outlook<sub>(e1)</sub>

FY16 Results

- Increased in EBIT due to strong sales of automobile-, semiconductor- and optical telecommunications-related components, in addition to a recovery in material prices

3.5 Ybn

3.2 Ybn

2.3 Ybn

## Service ratio

Maintain the ratio of EBIT from service business to overall at 50% or more

FY17 Outlook<sub>(e2)</sub>

FY17 Outlook<sub>(e1)</sub>

FY16 Results

- Maintained at 50% or more in line with a strong performance by service businesses

55%

61%

57%

Note: •(e1) denotes the figures announced on April 2017  
• FY16 Results are the figures before restated

•(e2) denotes the figures announced on October 2017

# Status of Progress on the Mid-Term Management Strategy (2)

R&D

Size of Investment	¥80 billion	Increase investments centered on the biotechnology and medical products business (Increase by 30% versus FY2013-FY2015)
FY17 Outlook(e2)	FY17 Outlook(e1)	FY16 Results
28.7 Ybn	27.8 Ybn	23.6 Ybn
<b>Science &amp; Medical Systems</b> <i>Strengthen existing operations and creation new core businesses, along with developing high-value-added dedicated machines</i>		
Biotechnology and Medical Products		<b>Main Investment Field: C&amp;I*, Genetic and bacterial testing</b>
cobas e801 - High-speed immunodiagnostic analyzer		Large immunodiagnostic analyzer featuring high throughput (300 tests per hour, 48 items)
3500 - Composite automated analyzer		Integrated three types of clinical tests, specifically clinical chemistry, immunodiagnostic, and blood coagulation testing, into a single analyzer
Developing compact CE sequencer		Entered into a collaboration with Promega Corporation in the U.S., and promoted the development
Scientific Systems		<b>Main Investment Field: Life science, Environment and energy, New materials, Food</b>
HM1000 - Screening equipment for phthalates		Corresponding to amended RoHS II directive by applying mass spectroscopy technology
Regulus Series - Field-emission scanning electron microscopes		Achieved high-resolution imaging at low accelerating voltages, thereby contributing to the observation and evaluation of material structures
<b>Electronic Device Systems</b> <i>Enhance the product portfolio and respond to new needs</i>		
Response to new needs of next-generation devices		Developed etching technology and next-generation models of high-acceleration SEM and various types of metrology and inspection equipment
Equipment for IoT market		Launched CD-SEMs for small-diameter semiconductor wafers and mirror electron inspection system

# Status of Progress on the Mid-Term Management Strategy (3)

Size of Investment **¥40 billion** →

- Manufacturing ability expansion, and technology strengthening to support business
- Strengthening collaboration with customers through demonstration facilities expansion

FY17 Outlook(e2)	FY17 Outlook(e1)	FY16 Results
22.3 Ybn	20.5 Ybn	14.4 Ybn

## Science & Medical Systems

### Biotechnology and Medical Products

Building extension at Hitachi High-Tech Kyushu (May 2017)

Production capacity at Hitachi High-Tech Kyushu was boosted to a level 4 times higher than before as a result of a building extension project



### Scientific Systems

Opened "Hitachi High-Tech Science Park" in the U.S. (June 2017)

- R&D site of Science & Medical Systems
- Boosting joint development and creating new business with customers and business partners



## Electronic Device Systems

Enhanced demo equipment aimed at capturing cutting-edge customers' processes

Ramped up development facilities at overseas site (North America)



Development site  
in North America

# Status of Progress on the Mid-Term Management Strategy (4)



## Science & Medical Systems

### Biotechnology and Medical Products

Starting a capital and business alliance in the genetic testing business with Precision System Science Co., Ltd. (PSS) (May 2017)

Size of Investment:  
Approx. 0.9 Ybn

Selling PSS's conventional products, and jointly develop a next-generation fully automated genetic testing system

Establishing a joint venture and starting alliance for expand business in Chinese IVD\*1 market (September 2016~)

Paid-in capital of joint venture:  
US\$ 3 million

- Strengthening the ability to deliver solutions in IVD business of China market
- Beginning collaboration with a major Chinese reagent manufacturer on equipment and reagent sales, and related services

Capital Participation in U.S. Company MagArray, Inc. (September 2017)

Size of Investment:  
Approx. 2.4 Ybn

Entering the cancer diagnostic testing service business accredited by CLIA\*2

## Scientific Systems

Business acquisition of Oxford Instruments plc Group's partial business (July 2017)

Size of Investment :  
Approx. 11.3 Ybn

- Establishing Hitachi High-Tech Analytical Science Ltd.
- Enhancing the lineup of atomic spectroscopy products, and strengthened the development, manufacturing/sales, and service structures

\*1 IVD: In-Vitro Diagnostics \*2 CLIA: Clinical Laboratory Improvement Amendments



## 3. FY17 Outlook

Note: YY/M denotes the year and month of the accounting period-end  
(e1) denotes the figures announced on April 2017  
(e2) denotes the figures announced on October 2017



# FY17 Outlook (Highlights)

(100 million yen)


	FY17 Outlook (e2)	YoY		vs. Previous Forecast (e1)	
		Increase / Decrease	Ratio	Increase / Decrease	Ratio
Revenues	6,900	+455	+7%	+100	+1%
Adjusted Operating Income	510	−63	−11%	+50	+11%
EBIT	520	−16	−3%	+60	+13%
Income before Income Taxes	520	−19	−4%	+60	+13%
Net Income	390	−12	−3%	+40	+11%
Net Income per Share	283.58 yen	−8.50 yen		+29.09 yen	
Cash Dividend per Share	80.00 yen	±0.00 yen		+5.00 yen	
ROE	10.5%	−1.4%		+1.0%	
FCF	+34	−282		+4	

Notes: FX rate estimate : 1USD=110 yen, 1EUR=125 yen



# FY17 Outlook

(Factors behind Changes from Previous Forecast: EBIT)



\*1 Strategic investment for growth: R&D, Depreciation and amortization, Personal expenses in overseas

\*2 HHA: Hitachi High-Tech Analytical Science Ltd.

## Science & Medical Systems

### Biotechnology and Medical Products

- Solid sales of clinical chemistry and immunodiagnostic analyzers in the global market, primarily in China
- Firm inquiries for immunodiagnostic analyzers driven by progress on regulatory registration of new immunodiagnostic analyzers in various countries
- Temporary inventory adjustments are expected to be completed within the year

### Scientific Systems

- **Electron Microscopes:** Demand in the Asian and European markets is increasing, while demand in the Japanese market is stagnant
- **Scientific Instruments:** The market for analyzers continues to grow by 2-3% per annum on a global basis, along with a recovery in demand worldwide, mainly to address LiB\* / fuel cells and the RoHS directive

\* LiB: Lithium-ion Battery

## Electronic Device Systems

### Logic

Investment is expected to be made as planned in response to demand in the server market

### Foundries


Lower demand for new equipment in connection with investment in 7 nm mass production, but investment in next-generation devices is expected in FY2018

### Memory

Major customers continue to invest in both 3D-NAND and DRAM, with firm orders received primarily for CD-SEM

## Revenues / EBIT Trend

(100 million yen)



\* Changes from previous forecast for the biotechnology and medical products business

## Main Accomplishments and Future Actions

### Accomplishments in the FY17/1H

- Launched the cobas e801 high-speed immunodiagnostic analyzer in the U.S. and Asia (excluding China)
- Cultivated a new market in Japan through the launch of the new 3500 composite automated analyzer
- Began collaboration with a major Chinese reagent manufacturer on analyzer and reagent sales, and related services
- Reagents for Verigene rapid bacterial testing systems became eligible for insurance and sales commenced in Japan
- Started a capital and business alliance with PSS<sup>\*1</sup>



Hitachi's composite automated analyzer 3500

### Future Actions

- Create new products and businesses
  - Develop next-generation new products (clinical analyzers and gene testers)
  - Promote a joint project with QIAGEN N.V. of Germany
  - Promote collaboration on a compact CE<sup>\*2</sup> sequencer with Promega Corporation of the U.S.
  - Enter the diagnostic testing service business (MagArray, Inc. of the U.S.)




Compact CE sequencer (completed image)

\*1 PSS: Precision System Science Co., Ltd.

\*2 CE: Capillary Electrophoresis

## Revenues / EBIT Trend

(100 million yen)



\* Changes from previous forecast for the scientific systems business


## Main Accomplishments and Future Actions

### Accomplishments in the FY17/1H

- Established Hitachi High-Tech Analytical Science Ltd. (HHA)
- Opened "Hitachi High-Tech Science Park" in the U.S.
- Launched strategic new products and dedicated machines
  - Regulus series of field-emission scanning electron microscopes, TM4000 series of tabletop microscopes and others
  - HM1000 screening equipment for phthalates
  - AminoSAAYA high-speed amino acid analyzer



Tabletop Microscope  
TM4000



Screening equipment  
for phthalates HM1000


### Future Actions

- Strengthen the global sales network and marketing functions
  - Establish research/new business development sites in the U.K. and China
  - Collaborate with HHA on marketing and sale
- Develop and expand sales of high value-added products/dedicated equipments
  - RoHS II -compliant /new X-ray fluorescence analyzer for quality control of batteries, the "ETHOS" new multipurpose composite FIB-SEM system

## Revenues / EBIT Trend

(100 million yen)

■ : EBIT



## Main Accomplishments and Future Actions

### Accomplishments in the FY17/1H

- Solid business performance centered on CD-SEMs, due to continued investment by major customers. Cumulative shipments of CD-SEMs have exceeded 5,000 units
- For responding the various needs, strengthen a product portfolio (CG6300, CR6300, CV5000)
- Increased the number of engineers and facilities primarily at overseas sites for process equipment (North America, Taiwan)



Advanced CD-SEM  
CG6300



High-Speed Defect  
Review SEM  
CR6300




Advanced High Voltage  
CD-SEM  
CV5000 Series

### Future Actions

- Further deepen early collaboration at sites worldwide : Strengthen a seamless response structure, from R&D to demonstration
- Enhancing product portfolio for the IoT market

## Revenues / EBIT Trend

(100 million yen)



\* 17/3 Figures are restarted

## Main Accomplishments and Future Actions

### Accomplishments in the FY17/1H

#### Social Infrastructure

- Railway inspections** - Won a large order for railway inspection equipment for the JR Group
- Control systems** - Obtained increased orders for BD-CUBE predictive diagnostic systems based on big data analysis

### Future Actions

#### Social Infrastructure

- Railway inspections** - Work to capture orders for railway inspection equipment mounted on operating railcars
- Control systems** - Expand sales of rapid microorganism testing systems



Lumione BL-1000

#### Industrial Infrastructure

- Auto assembly** - Steadily capture automotive LiB\* production equipment projects
- Thin-films** - Accelerate proposal-based sales activities for thin-film manufacturing equipment for the flexible devices market

\* LiB: Lithium-ion Battery

#### ICT Solutions


- IoT** - Provide solutions to management issues

### Revenues / EBIT Trend

(100 million yen)

\* Figures in parenthesis are transaction amounts that include net transaction amounts

■ : EBIT



\* 17/3 Figures are restarted

### Main Accomplishments and Future Actions

#### Accomplishments in the FY17/1H

- Shared Factory as a Service  
Commenced field trials in Thailand by introducing smart factory technology (certified as a "Project for Nurturing New Industries in ASEAN and Japan" by JETRO)



Shared Factory

- Solar power generation  
Commenced collaboration with Clean Max Enviro Solution Pvt. Ltd. on offering rooftop solar power generation solutions to Japanese companies in India

#### Future Actions

- Services for industrial parks  
Establish a business model to provide factory infrastructure and operation services to Japanese companies that have entered Thailand
- Expand rail transportation-related businesses  
Enhance the FVC\*2 service lineup by entering the parts and repair business in collaboration with UK companies, in addition to the procurement business

\*1 VCS: Value Chain Solution    \*2 FVC: Full Value Chain

## FY17 2nd Quarter Financial Results [IFRS]

***“Move forward with the Courage to Change and Be Changed”***

### Change to customer focus

Respond in detail to individualized needs, and provide solutions with highly expertise

### Change to autonomous-decentralized organization

Promote changing awareness to “Think, Decide and Act Autonomously” with the perspective of total optimization

**END**





## 4. Reference

Note: YY/M denotes the year and month of the accounting period-end  
(e1) denotes the figures announced on April 2017  
(e2) denotes the figures announced on October 2017

# FY17 Outlook (Revenues and EBIT by Segment)

(100 million yen)

		FY17 Outlook (e2)		FY16 Results		YoY		FY17 Outlook (e1)	
		Revenues	EBIT	Revenues	EBIT	Revenues	EBIT	Revenues	EBIT
	Science & Medical Systems	1,885	224	1,861	271	+1%	-47	1,905	253
	Electronic Device Systems	1,356	287	1,245	270	+9%	+16	1,263	197
	Industrial Systems	841	22	789	22	+7%	+0	877	26
	Advanced Industrial Products	2,981	35	2,629	22	+13%	+13	3,016	32
Total		6,900	520	6,445	536	+7%	-16	6,800	460

Notes: • Elimination such as subtractions in intersegment transactions, etc., are included in the totals  
• FY16 Figures are restarted

# Changes in Orders Received and Market Trend

## (Electronic Device Systems)

### Changes in Orders Received


(100 million yen)

	1Q	2Q	3Q	4Q	Total
17/3 Results	334	309	256	371	1,271
18/3 Forecast (April)	583		642		1,225
18/3 Forecast (July)	466		759		1,225
18/3 1H Results / 2H Forecast (October)	308	237	774		1,320


: Results  
 : Initial /  
 Previous forecasts  
 : Current forecast

### Semiconductor Manufacturing Equipment Market (Front-end)

(100 million USD)



### Revenues Ratio by Fields (Front-end Equip.)



# Capital Expenditure/ Depreciation Costs/ R&D / Revenues by Region

## ■ Capital Expenditure/Depreciation Costs/R&D

(100 million yen)

	17/3 1H	18/3 1H	YoY	17/3	18/3 <sub>(e2)</sub>	YoY
Capital Expenditure	46	72	+58%	144	223	+55%
Depreciation Costs	52	57	+9%	105	130	+23%
R&D	111	126	+14%	236	287	+21%

Note: Capital expenditure is based on acquisition base

## ■ Revenues by Region

(100 million yen)

		Japan	North America	Europe	Asia	Mainland China	Others	Total
17/3 1H	Revenues	1,160	293	459	1,085	402	51	3,048
	Ratio	38%	10%	15%	35%	13%	2%	100%
18/3 1H	Revenues	1,263	254	393	1,341	469	104	3,356
	Ratio	38%	7%	12%	40%	14%	3%	100%

# Changes in Quarterly Results

(100 million yen)			FY16 Q1	FY16 Q2	FY16 Q3	FY16 Q4	FY17 Q1	FY17 Q2
Revenues / EBIT	Science & Medical Systems	Revenues	458	468	422	513	397	478
		EBIT	92	53	72	53	45	52
	Electronic Device Systems	Revenues	279	293	347	326	381	321
		EBIT	78	58	91	44	114	64
	Industrial Systems	Revenues	151	198	150	289	152	185
		EBIT	−5	5	−2	24	−9	0
	Advanced Industrial Products	Revenues	631	617	675	705	729	746
		EBIT	4	4	9	5	11	8
	Others & Elimination/Corporate	Revenues	−24	−24	−14	−17	−17	−17
		EBIT	−5	−11	−4	−30	−5	−9
Total		Revenues	1,496	1,552	1,581	1,816	1,642	1,714
		EBIT	164	109	166	98	156	115
Income before Income Taxes			165	110	166	99	157	116
Net Income Attributable to Hitachi High-Technologies Corporation Stockholders			129	80	124	69	117	85

Notes: FY16 Figures are restarted

# Revenues Change in Main Business

(100 million yen)	FY16/Q1	FY16/Q2	FY16/Q3	FY16/Q4	FY17/Q1	FY17/Q2
<b>Science &amp; Medical Systems</b>	458	468	422	513	397	478
Electron Microscopes	50	88	68	94	70	88
Scientific Instr.	42	65	51	76	45	84
Medical Products	333	280	257	300	242	256
Biotechnology Products, Others	32	34	47	44	40	50
<b>Electronic Device Systems</b>	279	293	347	326	381	321
Process Equipment	146	139	165	136	160	158
Metrology & Inspection Equipment	131	152	181	189	219	161
Others	1	2	1	1	2	1
<b>Industrial Systems</b>	151	198	150	289	152	185
Social Infrastructure	76	78	77	123	68	82
Industrial Infrastructure	52	91	52	130	61	78
ICT Solutions	23	29	21	36	23	26
<b>Advanced Industrial Products</b>	631	617	675	705	729	746
Industrial Materials	198	189	207	228	240	239
Electronics Materials	201	195	217	222	231	246
VCS*	125	118	135	136	139	141
Fuel and Chemicals, Others	108	116	116	120	118	121

Notes : FY16 Figures are restarted

\* VCS: Value Chain Solution

## FY17 2nd Quarter Financial Results [IFRS]

### For further information

Yoshito Yokoi

General Manager, CSR Div.

TEL:+81-3-3504-5138 FAX:+81-3-3504-5943

E-mail: [yoshito.yokoi.jp@hitachi-hightech.com](mailto:yoshito.yokoi.jp@hitachi-hightech.com)

#### Notes on the data

1. All financial statement summaries and results predictions included in this presentation are on a consolidated basis unless otherwise stated. Numerical data is rounded off to the nearest 100 million yen.
2. In its disclosures, Hitachi High-Technologies may make statements that constitute forward-looking statements that reflect management's views with respect to certain future events and financial performance at the time of disclosure. Such statements are based on information available at the time of disclosure and may differ from actual results due to various external factors, both direct and indirect. In the event of a major discrepancy with the items disclosed, the Company will disclose on a case-by-case basis based on the law and/or the timely disclosure rules and regulations of the stock exchanges on which the Company is listed.

The information included in this material is for reference when investing, and not a canvass to invest. Brand selection and the final decision is at your own judgment.